Stock Alert for Orexigen Therapeutics Inc. (OREX)
  • Stock Alert for Boston Scientific Corp. (BSX)
  • Stock Alerts for MELA Sciences Inc. (MELA)
  • " />

    Stock Alert for Aeterna Zentaris Inc. (AEZS)

    Aeterna Zentaris Inc. (AEZS) is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. AEZS’s deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.

    Share Statistics (30-Aug-11) FY2009 FY2010 % Chg Q22010 Q22011 % Chg
    Symbol AEZS Revenue, $Mn 63.24 27.70 -56.2% 5.58 6.52 16.8%
    Current price $2.05 Gross marg. 73.9% 32.5% -56.0% 21.0% 15.8% -24.8%
    52wk Range: $0.93-$2.68 Oper. margin -89.5% -122.2%
    Avg Vol (3m): 3,152,100 Net margin -26.5% -102.7% 287.5% -110.8% -162.1% 46.3%
    Market Cap. 195.13M
    Shares Outstanding 95.18M EPS, $ -0.30 -0.38 26.7% -0.08 -0.12 50.0%

    Source:, SEC Filings

    Investment Highlights

    Shares of AEZS have gained 10.94% in the last five days; 2.53% in the last month; and 111.46% year-to-date.

    Shares of the Quebec-based cancer and endocrine drug maker jumped as much as 14% on Tuesday after it announced positive results of its completed Phase III study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

    In the press release, the Company said the results show that AEZS-130 reached its primary endpoint demonstrating >90% area-under-the-curve (AUC) of the Receiver Operating Characteristic (ROC) curve, which determines the level of specificity and sensitivity of the product. The Company added that it is currently proceeding with further detailed analyses of the data and preparing for a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the upcoming months, which would be followed by the filing of an NDA for the registration of AEZS-130 in the United States.

    The parameters of the study were achieved as agreed to with FDA under the Company’s Special Protocol Assessment (SPA). Importantly, the primary efficacy parameters show that the study achieved both specificity and sensitivity at a level of 90% or greater.  In addition, 8 of the 10 newly enrolled AGHD patients were correctly classified by a pre-specified peak GH threshold level. The use of AEZS-130 was shown to be safe and well tolerated overall throughout the completion of the trial.

    AEZS-130, a ghrelin agonist, is a novel orally active small molecule that stimulates the secretion of growth hormone.  It has been granted orphan-drug designation by the FDA for use as a diagnostic test for growth hormone deficiency. Aeterna Zentaris owns the worldwide rights to AEZS-130 which, if approved, would become the first orally administered diagnostic test for AGHD.

    AGHD affects 35,000 adult Americans, with 6,000 new adult patients diagnosed each year. Growth hormone not only plays an important role in growth from childhood to adulthood, but helps promote good health throughout life. It is usually characterized by low energy levels, decreased strength and exercise tolerance, increased weight or difficulty losing weight, emotional changes, anxiety and impaired sleep.

    Investors also welcomed news yesterday that a poster on AEZS’s novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado. The poster was presented by Matthias Gerlach Ph.D., senior director of medicinal chemistry for AEZS.


    Financial Summary

    AEZS reported revenues of $6.5 million for the three-month period ended June 30, 2011, as compared to $5.6 million for the same period in 2010. This increase is largely related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the U.S. dollar.

    Research and development costs, net of tax credits and grants were $5.6 million for the three-month period ended June 30, 2011, as compared to $5.4 million for the same period in 2010.

    Selling, general and administrative expenses were $3.4 million for the three-month period ended June 30, 2011, as compared to $3.7 million for the same period in 2010.

    Net finance (costs) income are comprised predominantly of net foreign exchange gains and losses, the change in fair value of the Company’s warrant liability and the unrealized gain on the Company’s short-term investment (2011 only).

    For the three-month period ended June 30, 2011, net finance costs totaled $2.6 million, as compared to a net finance income of $1.8 million for the same period in 2010. This significant increase in net finance costs is due to the change in fair value of the Company’s warrant liability. That change results from the periodic “mark-to-market” revaluation of currently outstanding share purchase warrants. Additionally, the increase is due to higher foreign exchange losses, which in turn resulted primarily from the comparative weakening of the U.S. dollar against the euro during the second quarter of 2011, partially offset by the unrealized gains on the Company’s short-term investment, which is carried at fair value. Neither the loss resulting from the periodic mark-to-market valuation of the warrants nor the gain resulting from the fair value adjustments to the short-term investment has resulted in any cash disbursement or cash receipt during the three-month period ended June 30, 2011.

    Net loss for the three-month period ended June 30, 2011, was $10.6 million, or $0.12 per basic and diluted share, as compared to $6.2 million, or $0.08 per basic and diluted share, for the same period in 2010. This increase is mainly related to higher net finance costs related to the periodic mark-to-market valuation of the warrants (non-cash) and higher foreign exchange losses, partly compensated by the unrealized gains on the Company’s short-term investment (non-cash).


    Financial Strength (30-Aug-2011)




    S&P 500

    Quick Ratio (MRQ) 2.90 2.92 1.78 0.74
    Current Ratio (MRQ) 3.15 3.52 2.18 1.09
    LT Debt to Equity (MRQ) 15.33 23.42 113.34
    Total Debt to Equity (MRQ) 18.00 29.73 154.01
    Interest Coverage (TTM) 17.95 1.67 22.82

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among 13 polled investment analysts. Against the Aeterna Zentaris Inc company.

    Analyst Detail






    No Opinion

    Latest 5 5 2 1 0 0
    4 weeks ago 5 4 3 1 0 0
    2 months ago 4 4 3 1 0 0
    3 months ago 4 3 3 1 0 0
    Last year 2 1 2 1 0 0


    Consensus Estimates Analysis

    # of Estimates




    1 Year Ago

    SALES (in millions)
    Quarter Ending Sep-11 7 6.67 6.93 6.40
    Quarter Ending Dec-11 7 6.71 7.21 6.25
    Year Ending Dec-11 10 26.48 28.59 20.88 17.50
    Year Ending Dec-12 10 27.55 41.20 13.50 12.45
    EARNINGS (per share)
    Quarter Ending Sep-11 9 -0.09 -0.08 -0.12 -0.07
    Quarter Ending Dec-11 8 -0.10 -0.08 -0.13 -0.07
    Year Ending Dec-11 12 -0.38 -0.26 -0.48 -0.39
    Year Ending Dec-12 11 -0.30 -0.15 -0.42 -0.39

    Technical Analysis


    AEZS is above the upper Bollinger Band, implying that it is currently extended from its recent trend.

    AEZS’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Aug30-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    EntreMed Inc. ENMD 1.43 16.53M n/a n/a n/a n/a
    Abbott Laboratories ABT 51.84 80.69B n/a n/a 2.08 1.99
    Celgene Corp. CELG 59.80 27.44B n/a n/a 5.84 5.21
    Merck & Co. Inc. MRK 32.89 101.33B n/a n/a 2.13 2.15
    Biotechnology Median       17.48 n/a 8.31 n/a
    AEterna Zentaris Inc. AEZS 2.07 196.94M n/a n/a 7.44 7.15

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *